GSK Plc - Director/PDMR Shareholding
12 Junho 2025 - 7:00AM
UK Regulatory
GSK Plc - Director/PDMR Shareholding
PR Newswire
LONDON, United Kingdom, June 12
GSK
plc (the
‘Company’)
Transaction
notification
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Emma
Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
9
(partnership shares)
|
|
|
|
£14.9465
|
9
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
18
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Julie
Brown
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
James
Ford
|
|
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Sally
Jackson
|
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
David
Redfern
|
|
b)
|
Position/status
|
President,
Corporate Development
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Regis
Simard
|
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Philip
Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Deborah
Waterhouse
|
|
b)
|
Position/status
|
CEO, ViiV
Healthcare and President, Global Health, GSK
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Victoria
Whyte
|
|
b)
|
Position/status
|
Company
Secretary
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares under the Company’s Share Reward Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£14.9465
|
8
(partnership shares)
|
|
|
|
£14.9465
|
8
(matching shares)
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16
Ordinary Shares
£14.9465
|
|
e)
|
Date of
the transaction
|
2025-06-10
|
|
f)
|
Place of
the transaction
|
London
Stock Exchange (XLON)
|
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Jun 2025 até Jul 2025
Gsk (LSE:GSK)
Gráfico Histórico do Ativo
De Jul 2024 até Jul 2025
